The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
复制标题
DOI：
10.1007/s00213-018-4885-9
复制
发表时间：
2018-07-01
影响因子：
3.4
通讯作者：
Ranganathan, Mohini
中科院分区：
文献类型：
--
作者：
Boggs, Douglas L.;Surti, Toral;Ranganathan, Mohini
初步证据表明大麻二酚（CBD）可能有效治疗神经退行性疾病；然而，CBD 从未被评估用于治疗与精神分裂症相关的认知障碍 (CIAS)。这项研究在临床试验中比较了 CBD 与安慰剂的认知、症状和副作用。这项研究是一项为期 6 周、随机、安慰剂对照、平行组、固定剂量研究，在 36 名稳定受试者中进行口服 CBD（600 毫克/天）或安慰剂增强研究 接受抗精神病药物治疗的患者被诊断患有慢性精神分裂症。所有受试者在基线和 6 周治疗结束时均完成了 MATRICS 共识认知电池 (MCCB)。在基线和每两周使用阳性和阴性症状量表 (PANSS) 评估精神病症状。时间或药物对 MCCB 综合评分没有主要影响，但观察到显着的药物 x 时间效应 (p = 0.02)。事后分析显示，只有安慰剂治疗的受试者随着时间的推移有所改善（p = 0.03）。随着时间的推移，PANSS 总分显着下降 (p < 0. 0001)，但没有显着的药物 x 时间相互作用 (p = 0.18)。 CBD 和安慰剂之间的副作用相似，唯一的例外是镇静作用，这在 CBD 组中更为普遍。 在研究剂量下，CBD 增加与稳定的接受抗精神病药物治疗的精神分裂症门诊患者的 MCCB 或 PANSS 评分改善无关。总体而言，CBD 的耐受性良好，没有出现情绪恶化、自杀倾向或运动副作用。
Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS).This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial.This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly.There was no main effect of time or drug on MCCB Composite score, but a significant drug x time effect was observed (p = 0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p = 0.03). There was a significant decrease in PANSS Total scores over time (p < 0. 0001) but there was no significant drug x time interaction (p = 0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group.At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.